Difference between revisions of "Plerixafor (Mozobil)"
m (→References) |
m (→References) |
||
| Line 16: | Line 16: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Subcutaneous medications]] | ||
[[Category:CXCR4 inhibitors]] | [[Category:CXCR4 inhibitors]] | ||
[[Category:Drugs FDA approved in 2008]] | [[Category:Drugs FDA approved in 2008]] | ||
| + | [[Category:PMDA approved drugs]] | ||
Revision as of 03:04, 9 August 2017
General information
Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
AMD3100.